Clinical Trial Update: Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD) [Phase 2]

View source ↗

Summary

Phase 2 trial of secukinumab (Cosentyx) for Necrobiosis Lipoidica Diabeticorum was terminated. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Necrobiosis Lipoidica Diabeticorum

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Necrobiosis Lipoidica Diabeticorum | Phase 2 | Status: TERMINATED | Results posted: 2024-05-17